Artificial Intelligence

With Jack Dorsey's backing, new app Divine resurrects Vine's spirit on a decentralized, AI-free platform. Can nostalgia challenge TikTok's dominance?

A modest 0.4% Q1 gain for Canadian pensions masks a dramatic story of geopolitical shocks, a booming energy sector, and a deep tech selloff.

Alibaba's Accio Work deploys AI "business teams" to SMEs, managing e-commerce and even launching physical products from scratch for a new era of business.

Seattle startup CounterX Therapeutics to present its novel overdose prevention drug at a top investor event, signaling new hope in the fentanyl crisis.

A new national ranking moves beyond funding and publications to reveal which U.S. research institutions are truly effective at creating real-world cures.

Once a hospital disinfectant, hypochlorous acid is now a skincare star. Magic Molecule's massive CVS launch signals a major shift in the beauty industry.

Snap CEO Evan Spiegel will headline Augmented World Expo, unveiling new tools from subsidiary Specs Inc. and charting a course for human-empowered spatial AI.

A new report shows most procurement and IT teams collaborate, but a failure on AI governance is stalling deployment and creating enterprise-wide risk.

As AI and usage-based pricing complicate finance, BillingPlatform launches RevVenue, an expert-led hub to help firms navigate a new era of compliance risk.

With new sensors that defy magnetic interference and a key investment from Plug and Play, XELA Robotics is set to revolutionize industrial automation in America.

The trading signal provider is rolling out new automated tools, touting major Q1 gains. But how do its claims stack up in a competitive, skeptical market?

With staggering 34% revenue growth, United Imaging is leveraging R&D and global expansion to disrupt the Western-dominated medical imaging market.

Brookfield Infrastructure reports a 10% FFO jump, fueled by a 46% surge in its data segment and a $1B capital recycling push, as it mulls a unified structure.

New GovTech firm LexiPoint, backed by Summit, launches a platform to turn complex regulations into auditable, consistent, and AI-governable decisions.

Shanghai's Vivacta Bio raises over $50M from top VCs to revolutionize cancer treatment with its pioneering in vivo CAR-T therapy, GT801.

A novel, FDA-cleared wound therapy is rolling out to military and veteran hospitals, aiming to rewrite the rules of healing for the most complex injuries.

Italian AI firm ELAI expands to the US, appointing veteran Kjersten Moody to help companies finally get real business results from their AI spend.

A new campaign aims to save a major research hub, igniting a debate over its economic benefits, medical breakthroughs, and the future of animal testing.

The company's Stevie® Awards highlight a critical truth: as AI strains enterprise systems, a robust, automated network is no longer optional.

A new patent for a biomarker-guided therapy offers hope for millions with treatment-resistant depression and extends market exclusivity for decades.